Market Cap 77.02M
Revenue (ttm) 62.04M
Net Income (ttm) -227.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -366.63%
Debt to Equity Ratio 0.00
Volume 583,900
Avg Vol 467,306
Day's Range N/A - N/A
Shares Out 84.77M
Stochastic %K 34%
Beta 1.61
Analysts Sell
Price Target $2.68

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 881 6500
Fax: 650 553 9659
Address:
111 Oyster Point Boulevard, South San Francisco, United States
KY3000
KY3000 Oct. 6 at 7:38 PM
$STRO dumpster fire
0 · Reply
YourDay
YourDay Oct. 6 at 6:32 AM
$STRO $1 soon
0 · Reply
betaino
betaino Oct. 1 at 11:18 AM
$STRO https://ir.sutrobio.com/news-events/news-releases/detail/218/sutro-biopharma-announces-operational-restructuring-intended-to-extend-cash-runway-through-key-milestones
0 · Reply
DARKP00L
DARKP00L Sep. 29 at 10:15 PM
$STRO 17:15 on Sep. 29 2025 Sutro Biopharma Reveals An Organizational Restructuring To Prioritize The Advancement Of Its Three ADC Programs And Research And Development Collaborations; The Restructuring, Is Expected To Extend The Company's Runway Into At Least Mid-2027; Restructuring To Result In Workforce Reduction Of One-Third Of Employees; Co. On Track To Advance STRO-004 Into Clinic This Year, With Initial Data Expected In 2026 #tradeideas
0 · Reply
DonCorleone77
DonCorleone77 Sep. 29 at 9:09 PM
$STRO Sutro Biopharma announces restructuring, workforce reduction of about 33%
0 · Reply
keypatience
keypatience Sep. 23 at 5:00 PM
0 · Reply
keypatience
keypatience Sep. 18 at 8:13 AM
$STRO Nasdaq sent Sutro a minimum bid price deficiency notice on 20 June 2025. They got the standard 180 calendar days to fix it. That window ends on 17 December 2025. To regain compliance they must have a closing bid at or above $1.00 for at least 10 consecutive business days within that window. As of today (18 Sep 2025), that leaves 90 days. Practically, the last feasible start for a 10-trading-day streak that finishes by the deadline is Thu, 4 Dec 2025. they miss the 17 Dec date, Nasdaq may grant a second 180-day period if Sutro transfers to the Nasdaq Capital Market and meets the other criteria. That would run to about 15 June 2026. Nasdaq can also require more than 10 days in some cases, up to 20, at its discretion.
0 · Reply
KY3000
KY3000 Sep. 17 at 7:54 PM
$STRO nonstop dumpster fire
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 12:21 PM
$STRO Excellent article that nails exactly where STRO stands right now. So if you want to update your STRO knowledge or get acquainted with STRO, this is a must read. https://beyondspx.com/quote/STRO/analysis/sutro-biopharma-xpresscf-platform-powers-a-focused-oncology-pipeline-resurgence-nasdaq-stro
0 · Reply
KY3000
KY3000 Sep. 7 at 3:51 PM
$STRO 004 might be an underdog, benchmarked to Pfizer TF ADC, will have data to compare to. Better safety profile at minimum will make it a contender
1 · Reply
Latest News on STRO
Sutro Biopharma to Participate in Upcoming Investor Conferences

May 1, 2025, 4:05 PM EDT - 5 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences


Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 14, 2025, 12:09 PM EDT - 7 months ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline


Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Jan 2, 2025, 6:28 PM EST - 9 months ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless


Sutro BioPharma: Good Stewardship Through Early Trials

Sep 14, 2023, 1:21 PM EDT - 2 years ago

Sutro BioPharma: Good Stewardship Through Early Trials


KY3000
KY3000 Oct. 6 at 7:38 PM
$STRO dumpster fire
0 · Reply
YourDay
YourDay Oct. 6 at 6:32 AM
$STRO $1 soon
0 · Reply
betaino
betaino Oct. 1 at 11:18 AM
$STRO https://ir.sutrobio.com/news-events/news-releases/detail/218/sutro-biopharma-announces-operational-restructuring-intended-to-extend-cash-runway-through-key-milestones
0 · Reply
DARKP00L
DARKP00L Sep. 29 at 10:15 PM
$STRO 17:15 on Sep. 29 2025 Sutro Biopharma Reveals An Organizational Restructuring To Prioritize The Advancement Of Its Three ADC Programs And Research And Development Collaborations; The Restructuring, Is Expected To Extend The Company's Runway Into At Least Mid-2027; Restructuring To Result In Workforce Reduction Of One-Third Of Employees; Co. On Track To Advance STRO-004 Into Clinic This Year, With Initial Data Expected In 2026 #tradeideas
0 · Reply
DonCorleone77
DonCorleone77 Sep. 29 at 9:09 PM
$STRO Sutro Biopharma announces restructuring, workforce reduction of about 33%
0 · Reply
keypatience
keypatience Sep. 23 at 5:00 PM
0 · Reply
keypatience
keypatience Sep. 18 at 8:13 AM
$STRO Nasdaq sent Sutro a minimum bid price deficiency notice on 20 June 2025. They got the standard 180 calendar days to fix it. That window ends on 17 December 2025. To regain compliance they must have a closing bid at or above $1.00 for at least 10 consecutive business days within that window. As of today (18 Sep 2025), that leaves 90 days. Practically, the last feasible start for a 10-trading-day streak that finishes by the deadline is Thu, 4 Dec 2025. they miss the 17 Dec date, Nasdaq may grant a second 180-day period if Sutro transfers to the Nasdaq Capital Market and meets the other criteria. That would run to about 15 June 2026. Nasdaq can also require more than 10 days in some cases, up to 20, at its discretion.
0 · Reply
KY3000
KY3000 Sep. 17 at 7:54 PM
$STRO nonstop dumpster fire
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 12:21 PM
$STRO Excellent article that nails exactly where STRO stands right now. So if you want to update your STRO knowledge or get acquainted with STRO, this is a must read. https://beyondspx.com/quote/STRO/analysis/sutro-biopharma-xpresscf-platform-powers-a-focused-oncology-pipeline-resurgence-nasdaq-stro
0 · Reply
KY3000
KY3000 Sep. 7 at 3:51 PM
$STRO 004 might be an underdog, benchmarked to Pfizer TF ADC, will have data to compare to. Better safety profile at minimum will make it a contender
1 · Reply
KY3000
KY3000 Sep. 6 at 5:04 PM
$STRO spinoff/or sell as a package , 002,003, and 006=100$MILL minimum. Every sutro collab involves share purchases, Astellas has made none.
0 · Reply
KY3000
KY3000 Sep. 6 at 4:57 PM
$STRO not mentioned in WF, maybe 2027 approval of VAX 31=60$MILL. With RFK drama, it’s time for vaxcyte to explore redo/new targets for all vaccines.
0 · Reply
KY3000
KY3000 Sep. 6 at 4:54 PM
$STRO listened to WF. 004 is benchmarked against Pfizer TF ADC(currently phase 3), 004 has been dosed up to 50 mg a kg, compared to 3mg a kg. Fully funded to initiate 3 IND. Astellas milestone 6-9 months(Chow)
0 · Reply
unearthedmosquito
unearthedmosquito Sep. 5 at 9:52 PM
$STRO Why has it up over 30% this week? any news? or is it really undervalued?
0 · Reply
Zaksab
Zaksab Sep. 5 at 3:45 PM
$STRO clearly something is afoot. the buying has been too keen for a while to suggest otherwise.
1 · Reply
Duskfall
Duskfall Sep. 5 at 3:45 PM
$STRO 👍
1 · Reply
KY3000
KY3000 Sep. 4 at 5:16 PM
$STRO RFK is an environmental lawyer. This is insane
0 · Reply
KY3000
KY3000 Sep. 3 at 9:49 PM
$STRO biotech rally is all about RFK senate hearing. A Leash or PR so bad trump fires him.
0 · Reply
Zaksab
Zaksab Sep. 3 at 8:33 PM
$STRO somewhat intruiging move
1 · Reply
B_man6969
B_man6969 Sep. 3 at 2:21 PM
$STRO wow
0 · Reply
Slitherin
Slitherin Sep. 2 at 7:47 PM
Ticker CARV has a tiny 3M float and $700M in assets with around $50M cash compared to a $10M Market cap. This could easily 2-3X. Rate cuts will boost banking stocks in September. $MATH $ALEC $STRO $AXTI $JFB on watch for AH
0 · Reply
Flok5000
Flok5000 Sep. 2 at 6:00 PM
$STRO seems different today… had multiple times in last weeks strong gains in the beginning but lost most at the end of the day.
1 · Reply